Crinecerfont is a novel orally administered CRF1 antagonist, approved by the U.S. Food and Drug Administration (FDA) in December 2024 for use alongside glucocorticoid therapy to help manage androgen concentrations in both pediatric (aged 4 and above) and adult patients with classic CAH (44, 45). This evidence concerns the gene CRHR1 and congenital adrenal hyperplasia.